eMedicine Specialties > Pediatrics: General Medicine > Allergy & Immunology

Complement Deficiency

Ruchir Agrawal, MD,, Chief, Allergy and Immunology, Aurora Sheboygan Clinic
Vishweswar Chilumkurti, MBBS, MPH, Rehabilitation Consultant, Career Employment Australia; Harumi Jyonouchi, MD, Associate Professor, Division of Pulmonary Allergy/Immunology and Infectious Diseases, Department of Pediatrics, UMDNJ-New Jersey Medical School

Updated: May 6, 2009

Introduction

Background

The complement system is a part of the immune system that is concerned with the innate immunity. It consists of numerous proteins that are activated by several triggering factors and start a chain of events in the human body. Because the pathway finally culminates in the creation of a cytolytic "membrane attack complex", it is a vital mechanism to fight infection.

In 1896, Jules Bordet, working at the Pasteur Institute in Paris, demonstrated that the factor in the blood serum capable of killing bacteria could be analyzed into two components: heat stable and heat labile. The heat labile component is what is now known as the "complement." The term complement was introduced by Ehrlich in the late 1890s.

In the 1900s, the complement system was understood to be a cytolytic system that primarily lysed bacteria and erythrocytes, which were sensitized with antibody. The complement system is currently known to contain at least 30 different proteins that are primarily formed in the liver and circulate in their inactive form. When activated, these proteins produce various complexes that play a major role in the innate and adaptive immune defense.

The 3 major pathways of complement activation are as follows:

1. The classical pathway (termed classical because it has been studied for >100 y and was the first pathway to be discovered)
2. The alternate pathway
3. The mannose-binding lectin (MBL) pathway

Deficiency of each component of the classical and alternate pathways is rare and comprises less than 1% of patients with primary immunodeficiency. Deficiency of components of the MBL pathway appears to be fairly common. Deficiency of early components of classical pathways has been associated with autoimmune disease, whereas deficiency of late components of complements lead to increased susceptibility to certain infections.

Scheme showing the cascade of events during the activation of the complement system.

Pathophysiology

The binding of C1 to antigen-antibody complexes that contain immunoglobulin M (IgM) or immunoglobulin G (IgG) antibodies (subclasses IgG1, IgG2, and IgG3) activates the classical pathway. Only these Ig isotypes have complement-binding sites in the Fc portion (CH2 domain of IgG and CH3 domain of IgM).

C1 is a large multimeric protein complex composed of 3 subunits: C1q, C1r, and C1s. C1r and C1s are serine esterases. The C1q must bind to the 2 Fc portions of immunoglobulin (Ig) heavy chains to initiate the complement cascade. The binding of C1q to the immune complex leads to enzymatic activation of C1r, which, in turn, cleaves and activates C1s. Activated C1s cleaves C4 into C4a and C4b. A single activated C1s can cleave numerous molecules of C4. This process leads to continuous formation of C4b but is inhibited by C1 esterase inhibitor enzyme (C1INH). Deficiency of C1INH leads to uninhibited formation of C4b and C4a.

C4b has an internal thioester bond that allows C4b to form covalent amide or ester linkages with the immune complex or the cells coated with antibodies. C2 then complexes with immune complex or cell surface–bound C4b and is cleaved into C2a (soluble component) and C2b by C1s. The C2b remains physically associated with C4b on the target cell surface, forming classical pathway C3 convertase (C4bC2b) that proteolytically cleaves C3 into C3a and C3b.

Once C3 is cleaved, all 3 complement activation pathways share the same terminal complement components (C5-C9). The classical pathway is important in antigen-specific adaptive immune defense because it is activated by antigen-antibody complexes. Complement activation via the classical pathway effectively lyses antibody-coated pyogenic bacteria such as Streptococcus pneumoniae and Haemophilus influenzae and cells coated with antibodies (often microbe-infected cells).

Mannose-binding lectin pathway

MBL is an acute-phase protein. It is secreted by hepatocytes as a part of the innate immune defense and activates complement cascade without antigen-antibody complex.

The MBL binds to mannose residues of polysaccharide on the microbial surface. The MBL-associated serine proteinases MASP-1 and MASP-2, analogous to C1r and C1s, cleave C2 and C4, forming C4b/C2b C3 convertase. The terminal components of complement are then activated. The MASP-1 can also directly cleave C3. The MBL has high structural homology with C1q protein and can bind with C1r and C1s, with subsequent activation of C4 and C2. The MBL pathway is generally thought to provide initial antigen-independent immune defense by rapid activation of complement cascade, directly recognizing sugar residues of microbes.

Alternative complement pathway - Properdin, factor B, and factor D

This pathway is activated by the combination of factor B, factor D, and properdin.

C3 in the plasma is continuously cleaved at a low rate (C3 tick over). If active C3 (C3b) attaches to the cell surface that lacks complement regulators, it permits rapid amplification of the complement cascade. Namely, factor B binds to C3b bound to the cell surface by forming amide or ester bonds. Factor B is then cleaved by factor D to generate Bb, which forms alternate pathway C3 convertase (C3bBb). Properdin stabilizes the C3bBb complex.

After the C3 convertase cleaves another C3 bound to the convertase, C3b combines with C3 convertase complex to form the alternate pathway C5 convertase. The C5 convertase further activates C5 to C5b, and sequential binding of terminal components C6, C7, C8, and C9 forms the membrane attack complex (MAC). The alternate pathway, along with the MBL pathway, plays an important role in innate immune defense in an antigen-independent manner. Moreover, even when C3b is generated by the other two pathways, it can form a complex with Bb that can further cleave more C3. Thus, the alternative pathway C3 convertase also amplifies complement activation initiated by other pathways.

C3 component

The central event in complement activation is proteolysis of C3, which produces C3b and C3a. As described above, C3b that is covalently attached to the cell surface or antigen-antibody complex initiates late steps of complement activation common to all 3 pathways, leading to the formation of lipid-soluble pore structures of the MAC. Along with C5a and C4a, C3a functions as an anaphylatoxin, inducing degranulation of mast cells and basophils. They also function as chemotactic factors for leukocytes. C3b is cleaved into C3d, C3dg, and iC3b (inactive C3b) by factor I. C3b and C3b cleavage products bind to complement receptors expressed on various cells and initiate other immune responses. Membrane-bound C3b and iC3b act as opsonins by binding receptors on neutrophils and macrophages. C3d and C3dg augment B-cell responses to antigen.

Late complement components - C5-C9

Converting C5 to C5a and C5b marks the activation of the terminal complement components. These events, in turn, lead to the formation of MAC by C5, C6, C7, C8, and C9. The MAC has a hydrophilic center that increases leakage of water and ions through the cell membrane, causing osmotic lysis and cell death.

Regulatory proteins

• C1INH: This is an inhibitory protein that regulates the classical pathway by covalently attaching to C1r2-C1s2, which dissociates C1r2-C1s2 tetramer from C1q and stops activation of the classical pathway.
• C4BP: This regulates the classical pathway by dissembling the C4bC2b complex. C4BP binds to C4b and blocks binding of C2b. Decay-accelerating factor (DAF) and complement receptor 1 (CR1) also bind to C4b to block C4b/C2b complex formation. DAF also displaces Bb from C3b.
• Factor I: Factor I regulates the complement activation by cleaving C3b. Factor I cleaves cell membrane–associated C3b into iC3b, C3d, and C3dg. It also cleaves C4b. CD46, factor H, C4BP, and CR1 all serve as cofactors for factor I–mediated cleavage of C3b/C4b.
• Factor H: Factor H promotes conversion of C3b to iC3b with factor I and displaces Bb from the alternate pathway C3 convertase (C3bBb). Cell membrane rich in sialic acid has higher binding affinity to factor H than to factor B. Because mammalian cells have higher sialic acid content than microbial cells, factor H prevents excessive complement activation in host cells but not in microbes. Factor H is the major regulator in the alternate pathway activation.
• CD59: CD59 expressed by many cell types inhibits binding of C9 to the membrane-inserted C5b-8 complex and limits MAC formation on host cells. CD59 is not expressed by microbial cells, which allow complement-mediated microbial cell lysis, sparing host cells.
• Membrane cofactor protein: This is a cofactor for factor I–mediated cleavage of C3b and C4b.
• DAF: This accelerates decay of C3/C5 convertase.
• CR1: This is the receptor for C3b/C4b and has an inhibitory profile similar to MCP and DAF.
• Properdin: This stabilizes AP convertases.
• Clusterin: This blocks fluid phase MAC.
• S protein: This blocks fluid phase MAC.
• Anaphylatoxin inactivator: This inactivates C3a, C4a, and C5a.
• Complement system: This is an important regulator of B-cell activation.

Naive B cells receive a stimulus from the B-cell receptor (BCR), leading to activation, elimination, or anergy. The strength of signal transduction of B cells and other antigen-presenting cells (eg, dendritic cells) depends not only on the affinity of antigen binding but also on positive signals via the B-cell coreceptor complex composed of CD21 (complement receptor 2 [CR2])/CD19/CD81(TAPA-1). CD21 binds to antigens via attached C3d while membrane Ig binds to the antigen. This allows an association of CD19 to BCR-associated kinases and rapid phosphorylation of the cytoplasmic tail of CD19, leading to activation of PI-3K, which, in turn, augments BCR-initiated B-cell activation signaling. Thus, the absence of CD21 expression by B cells leads to impaired humoral immune response to T-dependent antigens. This is characterized by a decrease in B-cell follicular retention and germinal center survival.

C3b cleavage products have also been shown to augment immune memory; C3 receptors expressed on dendritic cells bind to both immune complexes and antigen alone. CD21 (CR2) expressed on follicular dendritic cells serves to trap iC3b-coated and C3dg-coated antigen-antibody complex in the germinal center.

Complement deficiency

Deficiencies of the complement components have been reported for most of the constituents. These deficiencies can be inherited or acquired and complete or partial.

Complement deficiency and disease association includes the following:

• Deficiency of early components of classical pathway (C1, C4, C2): Autoimmune disease, especially systemic lupus erythematosus (SLE), is the most common presentation in patients with early component deficiency. The incidence rates of SLE in individuals with C1q and C4 are reported to be around 90% and 75%, respectively. Patients with C2 deficiency develop SLE with lesser frequency (around 15%). The proposed mechanisms of high incidence of autoimmune diseases include impaired clearance of immune complex and apoptotic cells and loss of complement-dependent B-cell tolerance. Recurrent bacterial infection is common in patients with C2 deficiency. Atherosclerosis also appears to occur at a higher frequency in individuals with C2 deficiency.
• MBL pathway
  • MBL deficiency is linked with frequent pyogenic infection, including pneumococcal infection in infants and young children. Severe pneumococcal disease is also reported in patients with MASP-2 deficiency.
  • In addition, MBL deficiency is 2-3 times as common in patients with SLE as in the general population. Others also report an increase in cardiovascular diseases associated with atherosclerosis in patients with MBL deficiency.
  • Schizophrenia is a severe mental disorder, with worldwide prevalence of 1–1.5%. Immunological research in schizophrenia indicates that infectious or autoimmune processes might play a role in the etiopathogenesis.
  • The complement system is a major mediator of innate immune defense against infection and contributes to many functions of the immune system including inflammation, opsonization and cell lysis. 
  • MBL activates the complement system via the lectin pathway.
  • Inherited MBL deficiency, common in most human populations, predisposes to infectious and autoimmune diseases.
  • A modulatory role for MBL in autoimmune disease has been reported. Investigations in Denmark and Hong Kong have suggested that MBL variant alleles are associated with both severity and early onset of disease in patients with rheumatoid arthritis.¹ However, patients with late-onset disease who were also homozygous for wild-type MBL genes were more likely to show evidence of persistent inflammation.
• Alternative pathway (properdin, factor B, factor D): This is associated with severe fulminant neisserial infections with a high mortality rate.
• C3, factor H, and factor I: Deficiency of these factors predisposes individuals to severe pyogenic bacterial infections. Factor H and factor I deficiencies cause secondary C3 deficiency with C3 consumption and impose the same infectious risk as primary C3 deficiency. Factor H deficiency is also associated with atypical (diarrhea-negative) hemolytic-uremic syndrome (HUS) and glomerulonephritis. C3 deficiency is associated with membranoproliferative glomerulonephritis.
• Terminal pathway (C5-C9): The lack of MAC formation results in severe recurrent infection by Neisseria gonorrhoeae or Neisseria meningitidis.
• C1INH: Primary and secondary deficiency of C1INH leads to uninhibited cleavage of C4 by C1s. Hereditary angioedema (HAE) is caused by heterozygous deficiency of C1INH and characterized by recurrent episodes of angioedema, which usually subside within 48-72 hours. C1INH is a regulator for C1r/C1s, as well as for Hageman factor, clotting factor XI, plasma kallikrein, and plasmin. Angioedema is caused by various mediators that involve these pathways.
• DAF and CD59: Defects of these 2 regulatory proteins make erythrocytes highly susceptible to complement-mediated cell lysis. This is typically seen in patients with paroxysmal nocturnal hemoglobinuria (PNH), which has clinical features that are characterized by hemoglobinuria and venous thrombosis of major vessels.

Frequency

United States

Complement deficiency can be acquired or inherited.² Acquired deficiency may be acutely caused by infection or in conjunction with chronic rheumatological or autoimmune disorders. Inherited deficiency is rare in the general population, with an estimated frequency of 0.03%, excluding MBL deficiency. MBL deficiency is thought to be fairly common, with a 3% frequency in general population. Likewise, MASP-2 deficiency may also be very common.

Among C1-C9 components, C2 deficiency is the most common, with an incidence rate of 1 case per 10,000 population.

International

Unlike in Western countries, C9 deficiency is the most common complement deficiency in Japan, excluding MBL pathway defects. High incidence of C9 deficiency is also reported in Korea.

Mortality/Morbidity

Properdin deficiency is associated with a high mortality rate due to fulminant infection with N meningitidis. Primary and secondary C3 deficiency present with severe recurrent pyogenic infections early in life, similar to those observed in patients with hypogammaglobulinemia, leading to high comorbidity. Secondary C3 deficiency occurs in factor H or I deficiency.

Sex

Most complement deficiencies equally affect males and females; however, properdin deficiency is X-linked recessive (ie, only males are affected). The male-to-female ratio of SLE is equal in patients with C1q and C4 deficiency. In general, SLE in individuals with complement deficiency is characterized by onset at earlier age, photosensitivity, and lower frequency of renal involvement. Patients with C2 deficiency and SLE typically present with low or negative antinuclear antibody (ANA) or anti-dsDNA antibody.

Age

Meningococcal disease and complement deficiency

Serum bactericidal activity (ie, bacterial lysis mediated by complement in the presence of specific antibody) is the main host defense against meningococcal disease. Newborns and infants are protected by maternal-derived transplacental IgG antibodies. Susceptibility is highest in children aged 3-24 months. Thereafter, the incidence of meningococcal disease declines as serum bactericidal activity against the various N meningitidis serogroups develops following nasal colonization. Ninety percent of all meningococcal disease occurs in children younger than 2 years. The median age of patients presenting with their initial episode of meningococcal disease is 3 years in the general population and 17 years in individuals with late complement component deficiency.

Clinical

History

The following may be associated with complement deficiency:

• Patient or family history of recurrent systemic infection caused by encapsulated bacteria, especially meningococci
• Family history of fulminant meningococcal disease occurring in males, suggestive of X-linked properdin deficiency
• Meningococcal disease occurring in persons older than 10 years, especially when caused by non–group B meningococci (especially serogroups Y and W-135)
• Family history of systemic lupus erythematosus (SLE) or occurrence of atypical features of SLE, especially negative lupus serology findings (negative antinuclear antibody [ANA] and negative dsDNA findings)
• Specific syndromes such as partial lipodystrophy, angioedema, and paroxysmal nocturnal hemoglobinuria (PNH): Consider evaluation of the complement system in patients with these syndromes.
• Recurrent pyogenic infection, including severe pneumococcal diseases in infants and young children with normal humoral immune workup findings

Physical

• Classical pathway deficiencies - C1, C4, and C2
  • Deficiencies of the classical complement pathway have been strongly linked to the development of autoimmune disorders, especially those in which excessive immune complexes are formed. Patients may develop collagen vascular disorders, mainly SLE. Ninety-five percent of patients with C1q deficiency, 75% of those with C4 deficiency, 30% of those who are deficient in C2, and 50-55% of those who are deficient in C1r and C1s (deficiency usually involves both C1r and C1s) develop collagen vascular diseases (mainly SLE). Evidence suggests that this may result from the combination of impaired complement-dependent B-cell tolerance and impaired clearance of immune complex and apoptotic cells.
  • C1 deficiency generally leads to severe immune complex disease with features of SLE and glomerulonephritis. Serum levels of anti-C1q antibodies were increased significantly in patients with SLE and proliferative nephritis. Among different serological parameters for assessing the renal activity of SLE, only anti-C1q antibodies titers showed significant differences between quiescent and active lupus nephritis. Patients with C2 deficiency are reported to reveal anti-C1q antibody in the absence of anti-dsDNA.
  • Complete C4 deficiency is rare. Two genes, C4A and C4B, encode the C4 complement. Both genes are highly polymorphic, and, to date, at least 35 different alleles have been described. Almost all patients with complete C4 deficiency have discoid or SLE, with or without associated glomerulonephritis.
  • C2 deficiency has been the most commonly reported classical pathway defect. Skin and joint manifestations are common, and renal disease is relatively rare. Patients with C2 deficiency are also reported to have recurrent or invasive infections.
• C3 deficiency
  • C3 deficiency is rare. Because of its importance as a convergence point of the 3 complement pathways, all patients with C3 deficiency develop recurrent, severe, pyrogenic infections early in life. Some patients may also develop membranoproliferative glomerulonephritis.
  • C3 deficiency leads to an inability to formulate membrane attack complex (MAC), thus markedly compromising chemotactic and bactericidal activities of the complement cascade.
  • Patients with C3 deficiency generally have less than 1% of the normal amount of C3 antigen and C3 function in their serum.
  • Because of ineffective opsonization of pathogens, patients with C3 deficiency present with severe recurrent pyogenic infections, mainly caused by meningococci and pneumococci.
  • According to published studies, 78% of patients have repeated infections, and 79% experience autoimmune disorders, such as arthralgia and vasculitic rashes, lupuslike syndrome, and membranoproliferative glomerulonephritis.
• Alternate pathway deficiencies (properdin, factor B, factor D)
  • These deficiencies are rare. Properdin deficiency is associated with increased risk of infections with encapsulated bacterial organisms. Patients often present with a history of invasive meningococcal diseases, as well as severe pneumococcal and H influenzae infection. Recurrent infections may be rare in patients with properdin deficiency because the classical pathway can take over the actions of the alternate pathway once antigen-specific adaptive immune responses are established with immunoglobulin (Ig)G and IgM antibody formation.
  • Only 3 adults with factor D deficiency have been described in the literature. A 6-day-old newborn boy with pneumococcal sepsis and meningitis was diagnosed with complete deficiency of factor D and diminished functional factor B. The addition of purified factor D restored the capacity of the patient's serum to generate the alternate pathway fluid-phase C3 convertase (C3bBbP) in response to zymosan. This also restored activity of factor B in the patient's serum. In contrast, the addition of factor B did not alter factor D activity in the serum, indicating requirement of factor D for function of factor B.
• Late complement component deficiencies - C5, C6, C7, C8, and C9
  • MAC cannot be formed; hence, bactericidal activity is depressed.
  • Patients are susceptible to recurrent pyogenic infections.
  • Patients typically present with meningococcal meningitis or extragenital gonococcal infection.
  • Two thirds of patients experience at least one episode of meningococcal disease, and as many as one half of patients experience recurrent neisserial infections.
  • Patients with C9 deficiency have the ability to kill Neisseria, but at a slower rate.
• Deficiency of C1INH (HAE): This leads to recurrent episodes of angioedema. See Angioedema (Hereditary).
• Mannose-binding lectin (MBL) pathway deficiency
  • Newborns with MBL deficiency are at increased risk for infection. Individuals with MBL deficiency have a higher propensity for severe infection in early life.
  • In young children and newborns with repeated infections, MBL defects should be considered.
  • Worsening clinical features are also reported in patients with rheumatoid arthritis and MBL deficiency.
  • In a study of patients with cystic fibrosis (CF) with or without MBL variant alleles, Garred et al found the following:¹
    • Lung function in carriers of MBL variant alleles was significantly reduced compared with patients with normal homozygotes.
    • The negative impact of variant alleles on lung function was especially confined to patients with CF and chronic Pseudomonas aeruginosa infection.
    • Burkholderia cepacia (previously named Pseudomonas cepacia) infection was significantly more frequent in patients with CF and MBL variant alleles.
    • Using a modified life table analysis, the authors estimated that the predicted age of survival was reduced by 8 years in patients with CF who carried variant alleles compared with normal homozygotes with CF.
• C3 nephritic factor (C3NeF) and mesangiocapillary glomerulonephritis (MCGN)
  • C3Nef is an autoantibody that binds to and stabilizes the C3 convertase (C3bBb).
  • The association of C3NeF and MCGN, especially MCGN type II, has been well defined. Different isotypes of C3NeF are recognized, the main one being an IgG autoantibody against factor H. Factor H is an important regulator of the C3 conversion step in the alternate pathway. C3NeF inhibits functions of factor H, which leads to overwhelming complement activation at the stage of C3 conversion. Continuous C3 activation in vivo results in the well-known consequences of very low serum levels of C3 in MCGN.
  • C3NeF may act directly within glomeruli to cause local complement activation and ensuing renal damage.
  • C3Nef is also associated with partial lipodystrophy.
• Factor H deficiency
  • Factor H deficiency is associated with hemolytic-uremic syndrome (HUS), especially in familial cases that involve homozygous factor H deficiency.
  • Factor H deficiency also occurs with membranoproliferative glomerulonephritis.
  • Parents have one half the normal levels of factor H.
  • HUS associated with factor H deficiency is characterized by verotoxin-negative (diarrhea-negative) HUS. Atypical and recurrent HUS is also seen in CD46 deficiency.

Causes

• Classical pathway deficiencies (C1, C4, C2) are inherited in an autosomal recessive pattern.
• C3 deficiency is inherited in an autosomal recessive pattern.
• No known homozygous deficiency of factor B has been reported, although one heterozygous case has been described. Properdin deficiency is the only X-linked complement deficiency. All reported cases of properdin deficiency involve males.
• Late complement component deficiencies (ie, C5, C6, C7, C8, C9) are inherited in an autosomal recessive fashion.

Differential Diagnoses

Agammaglobulinemia
Angioedema
Bruton Agammaglobulinemia
Common Variable Immunodeficiency
X-linked Immunodeficiency With Hyper IgM

Workup

Laboratory Studies

The following studies may be indicated in complement deficiency:

• Measurement of CH50 is the best screening test for deficiency of classical or terminal pathways. Hemolytic activity of the complement system is measured as hemolysis of sheep erythrocytes sensitized by specific antibodies. The degree of hemolysis is measured by CH50.
  • One CH50 unit is defined as the volume or dilution of serum that lyses 50% of erythrocytes in the reaction mixture.
  • AH50 is an analogous test to measure alternate-pathway function. This test is available only in specialized laboratories.
• Low levels of CH50 or AH50 warrant further evaluation. A low level of both CH50 and AH50 suggests deficiency of one of the components shared by both pathways (ie, C3-C9).
• A low CH50 level suggests deficiency of a classical or terminal C component.
  • C1-C8 deficiency: CH50 value is approximately 0.
  • C9 deficiency: CH50 value is approximately one half of the normal value.
• A low AH50 level suggests a deficiency in factor B, factor D, or properdin.
• Immunochemical methods are used to demonstrate specific complement protein deficiencies by using specific antibodies for each component. In certain cases, functional properties of complement components are diminished despite the presence of normal amounts of protein component detected by immunochemical measures. Functional assays are required for further evaluation.
• Acquired deficiencies vary with the severity of the underlying disorder.
  • Low C3 and C4 levels suggest activation of the classical pathway.
  • Low C3 and normal C4 levels suggest activation of the alternate pathway.
  • ANA is generally negative in immune complex diseases caused by complement deficiency.
• Hereditary angioedema (HAE) may be reflected as the following:
  • Low levels of C4 but normal levels of C3
  • C1 inhibitor (C1INH) - Low levels in type I (quantitative deficiency of C1INH) and may be normal in type II (functional deficiency of C1INH)
• Function of the mannose-binding lectin (MBL) pathway can be assessed with enzyme-linked immunosorbent assay (ELISA), which detects C4d bound to mannan that is coated to the plate after the test serum was incubated in the plate. Serum levels of MBL and MASP-1 and MASP-2 can be measured immunochemically, and some commercial laboratories offer such measurement techniques. MBL deficiency can be analyzed genetically (single nucleotide polymorphisms [SNPs] of exons of MBL) only in specialized laboratories.
• Plasma levels of regulatory proteins such as factor H and factor I can be measured in specialized laboratories.

Other Tests

• A recent study examined screening for C3 deficiency in newborns using microarrays.³

Treatment

Medical Care

• No specific treatment is available for genetically acquired complement deficiencies; however, acute attacks of hereditary angioedema (HAE), C1INH deficiency, have been successfully treated with infusion of vapor-heated C1 esterase inhibitor. Androgen therapy can be used to prevent HAE attacks. These treatments are recommended only in adults. A study in the Netherlands indicated efficacy of self-administration of plasma-derived C1INH concentrate for prevention and treatment of angioedema attacks in patients with C1INH deficiency.
• Only supportive therapy is available for other complement deficiencies. Fresh frozen plasma is used for emergent replacement of complement components.
• Genes have been cloned for individual component deficiencies. Therefore, gene therapy may be a choice in the future.
• All routine vaccines are recommended in complement deficiency.
  • Meningococcal vaccine is recommended for children with early or terminal complement component or properdin deficiencies.
  • Pneumococcal vaccine is recommended for deficiency of early components. The effects of influenza plus pneumococcal conjugate vaccination in preventing respiratory tract infections was recently studied.⁴

Consultations

• Consultation with a physician who specializes in immunodeficiency disorders may be considered.

Medication

Vaccine

Active immunization increases resistance to infection. Vaccines consist of microorganisms or cellular components, which act as antigens. Administration of the vaccine stimulates the production of antibodies with specific protective properties. Meningococcal disease is common among patients with terminal common complement pathway (C3, C5-9) deficiencies. Prevention of meningococcal meningitis is recommended.

Meningococcal vaccine (Menactra, Menomune-A/C/Y/W-135)

Isolated from groups A, C, Y, and W-135. Recommended for all individuals with known complement deficiency and those in close contact with the patient. The immunogenicity and clinical efficacy of serogroups A and C meningococcal vaccines have been well established. This vaccine does not confer any protection against serogroup B. The vaccine induces antibody response for serogroup A in individuals as young as 3 mo, but it is poorly immunogenic for serogroup C in recipients who are younger than 18-24 mo.

Dosing

Adult

0.5 mL SC

Pediatric

<2 years: Contraindicated
>2 years: Administer as in adults

Interactions

Coadministration with whole-cell pertussis or whole-cell typhoid vaccines may increase endotoxin content; immunosuppressive drugs may interfere with immune response

Contraindications

Documented hypersensitivity; avoid during course of acute illness; children <2 years; IV/IM/ID administration

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Deficiencies in late complement components (C3, C5-C9); do not administer IV/IM/ID; functional or actual asplenia; persons with laboratory or industrial exposure to N meningitidis aerosols; travelers to and residents of hyperendemic areas such as sub-Saharan Africa
For information concerning geographic areas in which vaccination is recommended, contact Centers for Disease Control and Prevention at (404) 332-4559

Androgenic agents

These agents may be used to prevent attacks associated with angioedema. Synthetic attenuated androgens taken prophylactically increase the serum concentration of C1NH.

Danazol (Danocrine)

Increases levels of C4 component of complement by increasing C1 esterase inhibitor, and thereby reduces attacks associated with angioedema.

Dosing

Adult

400-600 mg/d PO divided bid/tid

Pediatric

Not established

Interactions

Decreases insulin requirements and increases effects of anticoagulants; coadministration increases carbamazepine and cyclosporine blood levels

Contraindications

Documented hypersensitivity; seizure disorders; hepatic, renal, or hepatic insufficiency; pregnancy and lactation; conditions influenced by edema; porphyria

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Caution in renal, hepatic, or cardiac insufficiency; seizure disorders; peliosis hepatitis and benign hepatic adenoma have been observed with long-term therapy; thromboembolic events and pseudotumor cerebri; androgenlike effects, including weight gain, acne, hirsutism, edema, hair loss, voice changes, and menstrual disturbance

Follow-up

Deterrence/Prevention

• Prevention of infections and immediate treatment are important aspects of treatment in patients with complement deficiency. Treat acute infections with appropriate antibiotics and prevent with vaccination.
• All routine vaccines are recommended. Meningococcal, pneumococcal, and haemophilus vaccinations are recommended for patients and those who are in close contact with them.

Prognosis

• Properdin deficiency is associated with a high mortality rate.

Miscellaneous

Medicolegal Pitfalls

• Approximately 5-15% of patients with sporadic cases of meningococcal infections are deficient in C6, C7, C8, or C9. Screening for complement deficiencies is justified in all cases of systemic meningococcal disease.
• Screening for complement deficiencies is prudent in patients who present with recurrent infections, especially with encapsulated organisms, particularly patients with normal immunoglobulin (Ig) levels and antibody titers against vaccine antigens.

Multimedia

Media file 1: Scheme showing the cascade of events during the activation of the complement system.

References

1. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest. Aug 1999;104(4):431-7. [Medline].

2. Tedesco F. Inherited complement deficiencies and bacterial infections. Vaccine. Dec 30 2008;26 Suppl 8:I3-8. [Medline].

3. Janzi M, Sjoberg R, Wan J, Fischler B, et al. Screening for C3 deficiency in newborns using microarrays. PLoS ONE. 2009;4(4):e5321. [Medline].

4. [Best Evidence] Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial. J Pediatr. Dec 2008;153(6):764-70. [Medline].

5. AAP 2000 Red Book. Report of the Committee on Infectious Diseases. 25^th ed. 2000:56-7.

6. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. May 2005;94(5 Suppl 1):S1-63. [Medline].

7. Carroll MC. CD21/CD35 in B cell activation. Semin Immunol. Aug 1998;10(4):279-86. [Medline].

8. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol. Feb 1997;99(2):194-6. [Medline].

9. Cohen J. Meningococcal disease as a model to evaluate novel anti-sepsis strategies. Crit Care Med. Sep 2000;28(9 Suppl):S64-7. [Medline].

10. Endo M, Ohi H, Ohsawa I, et al. Complement activation through the lectin pathway in patients with Henoch-Schonlein purpura nephritis. Am J Kidney Dis. Mar 2000;35(3):401-7. [Medline].

11. Frank MM. Complement deficiencies. Pediatr Clin North Am. Dec 2000;47(6):1339-54. [Medline].

12. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA. Feb 1 1995;273(5):383-9. [Medline].

13. Kang HJ, Kim HS, Lee YK, et al. High incidence of complement C9 deficiency in Koreans. Ann Clin Lab Sci. 2005;35(2):144-8. [Medline].

14. Kumar A, Gupta R, Varghese T, et al. Anti-C1q antibody as a marker of disease activity in systemic lupus erythematosus. Indian J Med Res. Dec 1999;110:190-3. [Medline].

15. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. Apr 2006;117(4):904-8. [Medline].

16. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004;22:431-56. [Medline].

17. Moroni G, Trendelenburg M, Del Papa N, et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis. Mar 2001;37(3):490-8. [Medline].

18. Notarangelo L, Casanova JL, Conley ME, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol. Apr 2006;117(4):883-96. [Medline].

19. Ratnoff WD. Inherited deficiencies of complement in rheumatic diseases. Rheum Dis Clin North Am. Feb 1996;22(1):75-94. [Medline].

20. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore). Sep 1984;63(5):243-73. [Medline].

21. Rougier N, Kazatchkine MD, Rougier JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol. Dec 1998;9(12):2318-26. [Medline].

22. Salzman MB, Rubin LG. Meningococcemia. Infect Dis Clin North Am. Dec 1996;10(4):709-25. [Medline].

23. Sjoholm AG, Jonsson G, Braconier JH, et al. Complement deficiency and disease: an update. Mol Immunol. Jan 2006;43(1-2):78-85. [Medline].

24. Sturfelt G, Truedsson L. Complement and its breakdown products in SLE. Rheumatology (Oxford). Oct 2005;44(10):1227-32. [Medline].

25. Sullivan KE. Genetics of systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am. May 2000;26(2):229-56, v-vi. [Medline].

26. Ten RM, Carmona EM, Babovic-Vuksanovic D, Katzmann JA. Mannose-binding lectin deficiency associated with neutrophil chemotactic unresponsiveness to C5a. J Allergy Clin Immunol. Aug 1999;104(2 Pt 1):419-24. [Medline].

27. U. S. Department of Health and Human Services. Control and Prevention of Meningococcal Disease and Control and Prevention of Serogroup C Meningococcal Disease: Evaluation and Mangement of Suspected Outbreaks. Morbidity and Mortality Weekly Report. February 14, 1997;46:[Full Text].

28. Walport MJ. Complement. First of two parts. N Engl J Med. Apr 5 2001;344(14):1058-66. [Medline].

29. Walport MJ. Complement. Second of two parts. N Engl J Med. Apr 12 2001;344(15):1140-4. [Medline].

30. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. Jun 20 1996;334(25):1630-4. [Medline].

31. Weiss SJ, Ahmed AE, Bonagura VR. Complement factor D deficiency in an infant first seen with pneumococcal neonatal sepsis. J Allergy Clin Immunol. Dec 1998;102(6 Pt 1):1043-4. [Medline].

32. Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol. Apr 2004;113(4):585-93; quiz 594. [Medline].

33. West CD, McAdams AJ. The alternative pathway C3 convertase and glomerular deposits. Pediatr Nephrol. Jun 1999;13(5):448-53. [Medline].

34. Whaley K, Ruddy S. Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science. Sep 10 1976;193(4257):1011-3. [Medline].

35. Wiertsema SP, Herpers BL, Veenhoven RH, et al. Functional polymorphisms in the mannan-binding lectin 2 gene: effect on MBL levels and otitis media. J Allergy Clin Immunol. Jun 2006;117(6):1344-50. [Medline].

36. Williams DG. C3 nephritic factor and mesangiocapillary glomerulonephritis. Pediatr Nephrol. Feb 1997;11(1):96-8. [Medline].

Keywords

complement deficiency, complement system, mannose-binding lectin pathway, MBL pathway, classical pathway, alternative pathway, properdin, factor B, factor D, factor H, factor I, C3 component, late complement components, regulatory proteins, C1 inhibitor, C1INH, primary immunodeficiency, Streptococcus pneumoniae, Haemophilus influenzae, proteinuria, Fanconi syndrome, systemic lupus erythematosus, SLE, atherosclerosis, pneumococcal infection, MBL deficiency, schizophrenia, hemolytic-uremic syndrome, HUS, membranoproliferative glomerulonephritis, rheumatoid arthritis, Neisseria gonorrhoeae, Neisseria meningitidis, angioedema, collagen vascular disorders, cystic fibrosis, CF, treatment, diagnosis

Contributor Information and Disclosures

Author

Ruchir Agrawal, MD,, Chief, Allergy and Immunology, Aurora Sheboygan Clinic
Ruchir Agrawal, MD, is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma and Immunology, and American Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Vishweswar Chilumkurti, MBBS, MPH, Rehabilitation Consultant, Career Employment Australia
Disclosure: Nothing to disclose.

Harumi Jyonouchi, MD, Associate Professor, Division of Pulmonary Allergy/Immunology and Infectious Diseases, Department of Pediatrics, UMDNJ-New Jersey Medical School
Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Mucosal Immunology, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Medical Editor

Ann O'Neill Shigeoka, MD †, Former Clinical Associate Professor, Department of Pediatrics, Division of Immunology-Rheumatology, University of Utah School of Medicine
Ann O'Neill Shigeoka, MD † is a member of the following medical societies: American Federation for Medical Research, Clinical Immunology Society, Pediatric Infectious Diseases Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

John Wilson Georgitis, MD, Consulting Staff, Lafayette Allergy Services
John Wilson Georgitis, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American College of Chest Physicians, American Lung Association, American Medical Writers Association, and American Thoracic Society
Disclosure: Nothing to disclose.

CME Editor

David Pallares, MD, Clinical Assistant Professor, Department of Pediatrics, Division of Allergy and Immunology, University of Louisville
David Pallares, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology
Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

Relevant clinical guidelines include the following:

• Practice parameter for the diagnosis and management of primary immunodeficiency
• Prevention and control of meningococcal disease: Recommendations for use of meningococcal vaccines in pediatric patients
• Recommended immunization schedules for persons aged 0 through 18 years: United States, 2009

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)